Analysis of:
New Technique Allows Real-Time Observation Of Molecules During Chemical Reactions (www.medicalnewstoday.com)
To develop techniques to observe molecular reactions ( chemical and biological) is the holy-gale in the real biological world. Chemical bond formation and breaking are the central dogma in the life process, so to observe the reactions in real time will solve many...
Analysis of:
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso (phx.corporate-ir.net)
The future of microRNA molecule test is promising. It will open new avenue for personal medicine.
Analysis of:
Glenmark Pharmaceutical's Crofelemer enters phase-3 clinical trials (pharmalicensing.com)
Use of Crofelemer for HIV associated Diarrhea will add another arm for HIV patients.
Analysis of:
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia (www.astrazeneca.com)
Neuronal Nicotinic receptors are not the right choice for Cognitive Dysfunction in Schizophrenia.
Analysis of:
Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients (www.washingtonpost.com)
Higher chemodrug dose is a bad strategy for APL, AML and CML.
Initially it may benefit for long run basis it will many side effects and mortality rate will be higher.
Analysis of:
Generic Heart Drugs as Good as Brand-Name Counterparts (www.washingtonpost.com)
Generic heart drugs have equal therapeutic index as their brand counterparts
Analysis of:
Growth hormone not beneficial for ALS (pharmalive.com)
1. Growth hormone therapy may benefit for ALS 2. Small molecule agonist of IGF-1 have great future in ALS
Analysis of:
COPD Medicines: Risky or Safe? (www.webmd.com)
In a recent article it is noted that for users of Ipatropium bromide there was an increase in all death and cardiac death in the group studied. Theoretically at doses normally used there is not much of a corresponding mechanistic risk. Therefore at this time additional study must be done...
Analysis of:
Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma (www.therapeuticsdaily.com)
It is very good news atht Velcade approved for previously untreated multiple Myeloma. Velcade has multiple efficacy as treatmnet is concerned for other diseases too ( Diabetes-II, Cardiovascular disease) as the mechanism of action is same for those target ( proteasome inhibitors).